羟苯磺酸钙对早中期糖尿病性白内障患者的临床疗效观察

摘要

目的：观察羟苯磺酸钙对早中期糖尿病性白内障患者的临床疗效。　　方法：选取本院2010-01/2011-12初发期、未成熟期糖尿病性白内障住院患者共86例126眼，按照随机数字表将患者均分为对照组和观察组，对照组常规药物降糖治疗，观察组在对照组的基础上给予羟苯磺酸钙胶囊（0．5g/次，3次/d ）治疗，疗程6 mo。观察治疗前后两组患者空腹血糖、餐后血糖、糖化血红蛋白、血钙的变化，以及炎症指标超敏C反应蛋白（ hc-CRP ）、白介素-6（ IL-6）、肿瘤坏死因子-α（ TNF-α）的变化，评价两组患者治疗后白内障分期的进展率及缓解率。　　结果：两组患者治疗前后空腹血糖、餐后血糖、糖化血红蛋白及血钙均无明显变化，差异无统计学意义。对照组患者治疗前后hs-CRP， IL-6及TNF-α无明显变化，观察组治疗后hs-CRP，IL-6及TNF-α明显下降（P＜0．05），较对照组患者治疗后变化有统计学差异（P＜0．05）。对照组患者治疗后糖尿病性白内障分期缓解率及进展率分别为3.2％，21．0％，而治疗组患者经羟苯磺酸钙治疗，糖尿病性白内障分期缓解率及进展率分别为29．7％，7．8％，与对照组相比，差异有统计学意义（ P＜0．05）。　　结论：羟苯磺酸钙能提高糖尿病性白内障患者治疗效果，可能与改善患者微炎症状态有关。%AIM: To investigate the effect of calcium dobesilate in treating early-to-mid diabetic cataract patients. METHODS: Totally 86 patients (126 eyes) with diabetic cataract of incipient stage andimmature stage, treated in our hospital from January 2010 to December 2011, were enrolled. All patients were randomly divided into treatment group ( Group T ) and control group ( Group C) .Group T was treated with routine medicine glucose-lowering therapy. Group C was further treated with calcium dobesilate capsule (0.5g, 3 times per day) for six months.Preoperative and postoperative data of fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin, blood calcium level, hs-CRP, IL-6 and TNF-αlevel were observed.Progress rate and remission rate of cataract in different stages were evaluated in the two groups postoperatively. RESULTS: There was no significant difference in FBS, postprandial blood glucose, HBALC and blood calcium level between the two groups neither at the experiment onset nor after 6 months.As to the data of hs-CR, IL-6、and TNF-αlevel, there was no obvious change from preoperation to postoperation in Group C, while in observation group, those data decreased obviously ( P<0.05).And compared to Group C after treatment, there were statistical differences (P<0.05).As to the progress rate and remission rate of diabetic cataract in different stages, the data were 3.2%, 21.0% in Group C and 29.7%, 7.8%in Group T treated with calcium dobesilate. The difference was of statistical significance (P<0.05). CONCLUSION: Calcium dobesilate can improve the clinical stage of diabetic cataract patients, probably because of its function of improving the patients'microinflammatory state.